Hyperexcitability and epileptic seizures in a model of frontotemporal dementia

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 200-208

  García Cabrero, Ana M ^a,b   Guerrero López, Rosa ^a,b   Giráldez, Beatriz G ^a,b   Llorens Martín, María ^c,d   Ávila, Jesús ^c,d   Serratosa, José M ^a,b   Sánchez, Marina P ^a,b  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Astrocytosis; Chemoconvulsant; EEG; Epilepsy; FTDP 17 tau mutations; Hyperphosphorylated tau aggregates; Microgliosis

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN REGION; CHROMOSOME 17; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC DISCHARGE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; HIPPOCAMPUS; LATENT PERIOD; MICROGLIA; NERVE STIMULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEIZURE; SPIKE WAVE; TAU GENE;

AΒ; AD; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN; AMYLOID-Β; APP; ASTROCYTOSIS; CHEMOCONVULSANT; EEG; ELECTROENCEPHALOGRAPHY; EPILEPSY; FRONTOTEMPORAL DEMENTIA WITH PARKINSONISM LINKED TO CHROMOSOME 17; FTDP-17; FTDP-17 TAU MUTATIONS; GL; GRANULAR LAYER OF THE HIPPOCAMPUS; HUMAN TAU(VLW); HYPERPHOSPHORYLATED TAU AGGREGATES; MICROGLIOSIS; ML; MOLECULAR LAYER OF THE HIPPOCAMPUS; NEUROFIBRILLARY TANGLES; NFTS; PENTYLENETETRAZOL; PRESENILIN; PSEN; PTZ; TRANSGENE OF HUMAN TAU ISOFORM WITH 2 N-TERMINAL INSERTS, 4-MICROTUBULE-BINDING-REPEAT ELEMENTS AND WITH G272V (V), P301L (L), AND R406W (W) MUTATIONS UNDER THE CONTROL OF THE NEURON-SPECIFIC THY-1 PROMOTER;

ANIMALS; BRAIN; CALCIUM-BINDING PROTEINS; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FRONTOTEMPORAL DEMENTIA; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; PENTYLENETETRAZOLE; TAU PROTEINS; TRANSCRIPTION FACTORS; VIDEO RECORDING;

EID: 84880169805     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.06.005     Document Type: Article

References (54)

1. Amatniek J.C., et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006, 47:867-872.
2. Arrasate M., et al. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett. 1999, 446:199-202.
3. Avila J., et al. Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 2004, 84:361-384.
4. Barten D.M., et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 2012, 32:7137-7145.
5. Bellucci A., et al. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 2011, 8:221-229.
6. Blom N., et al. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 1999, 294:1351-1362.
7. Bugiani O. FTDP-17: phenotypical heterogeneity within P301S. Ann. Neurol. 2000, 48:126.
8. Bugiani O., et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J. Neuropathol. Exp. Neurol. 1999, 58:667-677.
9. Cabrejo L., et al. Phenotype associated with APP duplication in five families. Brain 2006, 129:2966-2976.
10. Crespo-Biel N., et al. Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem. Int. 2007, 50:435-442.
11. Engel T., et al. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 2006, 27:1258-1268.
12. Foster N.L., et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol. 1997, 41:706-715.
13. Garcia-Ayllon M.S., et al. Revisiting the role of acetylcholinesterase in Alzheimer's disease: cross-talk with P-tau and beta-amyloid. Front. Mol. Neurosci. 2011, 4:22.
14. Goedert M., et al. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006254.
15. Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:4913-4917.
16. Guerrero R., et al. Park2-null/tau transgenic mice reveal a functional relationship between parkin and tau. J. Alzheimers Dis. 2008, 13:161-172.
17. Guerrero R., et al. Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene. Acta Neuropathol. 2009, 117:159-168.
18. Han D., Paudel H.K. FTDP-17 missense mutations site-specifically inhibit as well as promote dephosphorylation of microtubule-associated protein tau by protein phosphatases of HEK-293 cell extract. Neurochem. Int. 2009, 54:14-27.
19. Holth J.K., et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci. 2013, 33:1651-1659.
20. Hutton M., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
21. Ittner L.M., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
22. Jayadev S., et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 2010, 133:1143-1154.
23. Jones N.C., et al. Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol. Dis. 2012, 45:897-901.
24. Kim D.Y., et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 2007, 9:755-764.
25. Larner A.J., Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J. Neurol. 2006, 253:139-158.
26. Liang Z., et al. Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J. Alzheimers Dis. 2009, 17:531-539.
27. Lim F., et al. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell. Neurosci. 2001, 18:702-714.
28. Limon A., et al. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10071-10076.
29. Llorens-Martin M., et al. Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons. Hippocampus 2006, 16:480-490.
30. Llorens-Martin M., et al. Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice. Neuroscience 2011, 196:215-227.
31. Mendez M.F., et al. Seizures in Alzheimer's disease: clinicopathologic study. J. Geriatr. Psychiatry Neurol. 1994, 7:230-233.
32. Murakami T., et al. Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. Am. J. Pathol. 2006, 169:1365-1375.
33. O'Callaghan J.P., Jensen K.F. Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. Neurotoxicology 1992, 13:113-122.
34. Otvos L., et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 1994, 39:669-673.
35. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
36. Palop J.J., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
37. Perez M., et al. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. J. Neurochem. 2000, 74:2583-2589.
38. Perez M., et al. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience 2005, 130:339-347.
39. Racine R.J. Modification of seizure activity by electrical stimulation II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
40. Roberson E.D., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
41. Roberson E.D., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
42. Romanelli M.F., et al. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch. Neurol. 1990, 47:847-850.
43. Scarmeas N., et al. Seizures in Alzheimer disease: who, when, and how common?. Arch. Neurol. 2009, 66:992-997.
44. Scharfman H.E. Untangling Alzheimer's disease and epilepsy. Epilepsy Curr. 2012, 12:178-183.
45. Schellenberg G.D., Montine T.J. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 2012, 124(3):305-323.
46. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271:18295-18298.
47. Shitak R., et al. Anti-seizure efficacy of nimodipine in pentylenetetrazole and kainic acid combined seizure models in mice. Indian J. Physiol. Pharmacol. 2006, 50:265-272.
48. Squire L.R. The legacy of patient H.M. for neuroscience. Neuron 2009, 61:6-9.
49. Szot P. Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia 2012, 53(Suppl. 1):61-66.
50. Tian F.F., et al. Potential roles of Cdk5/p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model. Clin. Lab. 2010, 56:127-136.
51. Verret L., et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.
52. Wszolek Z.K., et al. Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet J. Rare Dis. 2006, 1:30.
53. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
54. Yu F.H., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat. Neurosci. 2006, 9:1142-1149.